Treatment Information

Back

Kidney (Renal) Cancer treatment details. Biologic therapy.

Churchill Hospital, Oxford, United Kingdom.

Survival: monthsCountry:United Kingdom
Toxiciy Grade:4City/State/Province:Oxford
Treatments:Biologic therapyHospital:Churchill Hospital
Drugs:Journal:Link
Date:Oct 2003

Description:

Patients: This Phase II study involved 16 patients with advanced renal cancer; 11 men and 5 women. Median age was 59. Eight had undergone prior nephrectomy. Most had undergone other previous treatments.

Treatment: The treatment consisted of bryostatin-I. Bryostatin-I is a biological agent that has been isolated from a marine organism – the bryzoan, Bigula neritina.

Toxicity: Grade 4 toxicities possibly related to the treatment included dyskinetic tongue movements, hematuria, and skin rash. Other common side effects included myalgia, fatigue, nausea, headache, vomiting, anorexia, anemia and lymphopenia.

Results: No complete responses or partial responses were seen.

Correspondence: Dr. A.L. Harris




Back